RBPMS: a protein that helps heart muscle genes and function
RBPMS, a novel RNA splicing regulator of cardiac function and disease
This work looks at whether the protein RBPMS helps keep heart muscle cells working and can protect against heart failure and chemotherapy-related heart damage.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11361465 on NIH RePORTER |
What this research studies
You will hear about lab and animal work that studies how RBPMS controls RNA splicing in heart muscle cells and affects their ability to contract. The team measures RBPMS levels in patient heart tissue and uses animal models and human induced pluripotent stem cell–derived cardiomyocytes treated with doxorubicin to model heart injury. They test what happens when RBPMS is missing or increased, and track changes in gene splicing, heart cell function, and survival. The goal is to find whether restoring or boosting RBPMS activity could protect the heart and guide future treatments.
Who could benefit from this research
Good fit: Adults with heart failure or adults who have experienced or are at risk for doxorubicin (chemotherapy)–related heart injury would be the most relevant candidates for related human studies or sample donation.
Not a fit: People without heart disease, children under 21, or those with unrelated medical conditions are unlikely to benefit directly from this specific research.
Why it matters
Potential benefit: If successful, this research could point to new ways to protect or repair heart muscle, including strategies to prevent chemotherapy-related heart damage.
How similar studies have performed: Previous laboratory studies show RBPMS is important for heart cell development and that increasing RBPMS helped lab-grown human heart cells survive doxorubicin, but applying this approach to patients is still new.
Where this research is happening
Philadelphia, United States
- Temple Univ of the Commonwealth — Philadelphia, United States (Active)
Researchers
- Principal investigator: Gan, Peiheng — Temple Univ of the Commonwealth
- Study coordinator: Gan, Peiheng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.